The clinical and therapeutic implications of mTOR are widespread and continue to expand.Abnormal mTOR activity, leading to excessive cellular growth and proliferation, has been implicated in the pathophysiology of numerous human cancers, including both sporadic,isolated tumors of specific organs and multiorgan, genetic tumor syndromes (Guertin and Sabatini, 2007). In many of these cases, specific mutations of some component of the mTOR signaling pathway have been documented, resulting in hyperactivation of mTOR or its downstream effectors. Besides cancer, dysregulation of mTOR has also been implicated in a number of other diseases, involving metabolic or environmental derangements, such as diabetes, obesity, cardiovascular disease, and neurodegenerative disorders (Tsang et al.,2007). From a translational standpoint, the potential role of mTOR in the pathophysiology ofthese various disorders has immediate therapeutic implications, as a number of clinically available drugs exist that inhibit mTOR, including the prototype, rapamycin. Thus, rapamycin and other mTOR inhibitors are already being tested in clinical trials for various cancers and other diseases (Dancey, 2006; Tsang et al., 2007).
Overall, mTOR appears to serve as a master switch responding to different physiological
and pathological stimuli to maintain homeostasis by regulating cellular growth,
proliferation, and survival. mTOR is increasingly recognized to be involved in a large
spectrum of physiological functions under normal conditions and to be dysregulated in a diverse group of diseases. mTOR inhibitors, such as rapamycin, are being considered or are already in clinical trials for a number of these diseases. Based on the physiological and pathophysiological properties of mTOR, it is reasonable to hypothesize that mTOR
signaling could be involved in mechanisms of epileptogenesis. In the remainder of this
review, evidence for the role of mTOR in epileptogenesis and the potential utility of mTOR inhibitors as anti-epileptogenic agents will be analyzed in different types of epilepsies, starting with the genetic epilepsy, Tuberous Sclerosis Complex, and other tumor- or cortical malformation-associated epilepsies, and extending to more common, acquired epilepsies.
æ»ä½èè¨ï¼ç 究似ä¹å å½ä¸»å¼å ³ååºä¸åççç
åç çåºæ¿ä¿æ平衡çè°èç»èçé¿ï¼
æ©æ£ï¼åçåãä¸æ£æ¥ç被确认åä¸å¤§
é¢è°±çççåè½å¨æ£å¸¸æ¡ä»¶åéè°çä¸ç»ä¸åçç¾ç ãæå¶åï¼å¦é·å¸éç´ ï¼æ£å¨èèæå·²ç»å¨ä¸´åºè¯éªä¸çä¸äºè¿äºç¾ç ãåºäºççåç çççç¹æ§çé¶èç½ï¼å®æ¯åççå设çç 究
ä¿¡å·å¯è½åä¸ç«ç«åç æºå¶ãå¨ä½ä¸çè¿
审æ¥ï¼è¯æ®çä½ç¨ï¼å¨ç«ç«åæ½å¨çå®ç¨æå¶åä½ä¸ºåè´ç«åå°åæå¨ä¸åç±»åçç«ç«ï¼å¼å§ä¸éä¼ æ§ç«ç«ï¼ç»èæ§ç¡¬åçï¼ä¸å ¶ä»è¿ç¤æç®è´¨ç¸å½¢ç¸å ³æ§ç«ç«ï¼å¹¶å»¶ä¼¸å°æ´ä¸ºå¸¸è§ï¼å天ç«ç«ã追é®
ä¸å¤é顺å ä¸çå°±æ¯googleç¿»è¯åºæ¥ç 没è¯æ è½ä¸è½å¥½å¥½ç¿»è¯ä¸å
总的来说,似乎作为耐受总开关的不同的生理反应
和病理刺激维持内环境稳定,通过调节细胞生长,
增生和存活率。耐受日益被参与一个大
光谱的生理功能在正常条件下,在一个多元的集体特异表达基因疾病。耐受抑制剂,如雷帕霉素,正在考虑或已经在临床试验中许多这些疾病。基于生理和病理生理特性的耐受,可以合理假设耐受
信号可以epileptogenesis参与机制。 在剩馀的
审查证据的角色在epileptogenesis耐受和潜力的效用的inhibito耐受追问
能不能通顺点啊 直接google翻译不行呐